169 related articles for article (PubMed ID: 19360407)
1. BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.
Rusakiewicz S; Madrigal A; Travers P; Dodi AI
Cancer Immunol Immunother; 2009 Sep; 58(9):1449-57. PubMed ID: 19360407
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
3. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
4. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.
Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Roosnek E; Hertenstein B; Schipper RF; Schreuder GM; D'Amaro J; Oudshoorn M; van Biezen JH; Hermans J; Willemze R; Niederwieser D
Blood; 1999 Jun; 93(11):3863-5. PubMed ID: 10339494
[TBL] [Abstract][Full Text] [Related]
5. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
[TBL] [Abstract][Full Text] [Related]
6. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
[TBL] [Abstract][Full Text] [Related]
8. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.
Posthuma EF; van Bergen CA; Kester MG; de Paus RA; van Veelen PA; de Ru AH; Drijfhout JW; Lurvink EG; Willemze R; Falkenburg JH
Haematologica; 2004 Sep; 89(9):1062-71. PubMed ID: 15377467
[TBL] [Abstract][Full Text] [Related]
9. Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses.
Rusakiewicz S; Aubert G; Clark RE; Madrigal AJ; Dodi AI; Travers PJ
Cancer Immunol Immunother; 2009 Sep; 58(9):1459-70. PubMed ID: 19415272
[TBL] [Abstract][Full Text] [Related]
10. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
Norbury LC; Clark RE; Christmas SE
Br J Haematol; 2000 Jun; 109(3):616-21. PubMed ID: 10886212
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.
Butt NM; Wang L; Abu-Eisha HM; Christmas SE; Clark RE
Blood; 2004 Apr; 103(8):3245. PubMed ID: 15070713
[No Abstract] [Full Text] [Related]
12. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
Wagner WM; Ouyang Q; Pawelec G
Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
[TBL] [Abstract][Full Text] [Related]
13. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
[TBL] [Abstract][Full Text] [Related]
14. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia as an immunological target.
Lim SH; Coleman S
Am J Hematol; 1997 Jan; 54(1):61-7. PubMed ID: 8980262
[TBL] [Abstract][Full Text] [Related]
17. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia.
Wagner WM; Ouyang Q; Pawelec G
Leukemia; 2002 Nov; 16(11):2341-3. PubMed ID: 12399986
[No Abstract] [Full Text] [Related]
18. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
19. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Clark RE; Dodi IA; Hill SC; Lill JR; Aubert G; Macintyre AR; Rojas J; Bourdon A; Bonner PL; Wang L; Christmas SE; Travers PJ; Creaser CS; Rees RC; Madrigal JA
Blood; 2001 Nov; 98(10):2887-93. PubMed ID: 11698267
[TBL] [Abstract][Full Text] [Related]
20. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
